Adjuvanted influenza virus vaccine inactivated trivalent - Vaxine

Drug Profile

Adjuvanted influenza virus vaccine inactivated trivalent - Vaxine

Alternative Names: Adjuvanted seasonal 2008 trivalent inactivated influenza vaccine - Vaxine

Latest Information Update: 27 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxine
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 27 Sep 2017 No recent reports on development identified - Phase-I/II for Influenza virus infections (Prevention) in Australia (IM)
  • 16 Sep 2015 Vaxine completes a phase I/II trial for Influenza virus infections (Prevention, In elderly subjects and patients with chronic diseases) in Australia (ACTRN12608000364370)
  • 20 Apr 2010 Clinical development of the Adjuvanted seasonal influenza vaccine is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top